What are Antisense Oligonucleotides?
Antisense oligonucleotides (ASOs) are short engineered nucleic acid sequences designed to specifically bind to target messenger RNA (mRNA) molecules and interfere or "silence" gene expression. ASOs are generally 15-25 nucleotides in length and are chemically modified to increase their stability and binding affinity for mRNA. By binding to mRNA, ASOs can block translation and effectively decrease or silence the production of a target disease-causing protein from that mRNA. ASOs represent a targeted gene-silencing approach that is distinct from other nucleic acid therapeutics such as small interfering RNAs (siRNAs).

Mechanisms of Action

There are a few key mechanisms by which ASOs can interfere with mRNA function:

- Ribonuclease H (RNase H) recruitment: Conventional ASOs contain a backbone that can recruit the endogenous RNase H enzyme. RNase H degrades the mRNA strand of an RNA-DNA duplex, effectively destroying the mRNA and preventing translation. This is one of the primary mechanisms of ASO activity.

- Steric blocking of translation: "Gapmer" ASOs contain a central region comprised of DNA-like nucleotides that are bound by the target mRNA, while flanking regions contain chemical modifications that prevent RNase H recruitment. This design sterically blocks ribosomal activity and translation without degrading the mRNA.

- Splice-modulating activity: Some ASOs are designed to bind pre-mRNA sequences and alter splicing by recruiting proteins involved in spliceosome assembly. This can promote exon skipping or inclusion during splicing.

- Up-regulation of RNA degradation: Binding of ASOs to mRNA can recruit endonucleases or exonucleases that increase mRNA decay independent of RNase H activity.

Therapeutic Applications

Due to their high target specificity and gene silencing effects, ASOs have enormous potential as therapeutics for various genetic disorders. Some key disease areas where ASO drugs have been developed or are in clinical trials include:

Duchenne Muscular Dystrophy: Exon-skipping ASO drugs like Eteplirsen and Golodirsen are approved for DMD patients by targeting specific mutations and inducing skipping of defective exons to restore the dystrophin reading frame.

Hereditary Transthyretin Amyloidosis: Patisiran was the first FDA-approved RNAi therapeutic. It targets transthyretin (TTR) mRNA to reduce pathogenic protein amyloid deposits.

Familial Amyloid Polyneuropathy: Inotersen targets TTR mRNA and is approved for this condition.

Huntington's Disease: IONIS-HTTRx lowers levels of the mutant huntingtin protein by targeting its mRNA. Currently in Phase 3 trials.

Spinal Muscular Atrophy: Nusinersen binds upstream of exon 7 in SMN2 pre-mRNA, promoting inclusion of this exon and production of functional SMN protein.

Hepatic diseases: Volanesorsen targets apolipoprotein(a) mRNA to treat familial chylomicronemia syndrome and potentially cardiovascular disease.

Beyond these, ASOs also show therapeutic potential for neurodegenerative disorders, cancer, and viral infections by targeting crucial genes and gene networks. Hundreds of ASO drugs are in development to expand the applications of this platform technology.

Challenges and Improvements

While very promising, several challenges still need to be addressed for ASO therapeutics:

- Off-target effects: Ensuring ASOs only bind their intended target mRNA with high specificity remains an area of research. Improved chemical modifications aim to enhance target specificity.

- Delivery challenges: Getting ASOs to penetrate tissues and cells, especially across the blood-brain barrier, remains difficult. Novel delivery technologies are being explored.

- Excretion and dosing: Repeated high doses may be required due to rapid renal excretion of ASOs. Strategies to enhance tissue retention time are underway.

- Immunogenicity: Unmodified ASO backbones can activate immune responses including complement activation. Fully chemically modified ASOs show lower immunogenicity.

- toxicities: As with other nucleic acid drugs, potential toxicities from off-target effects or excessive target downregulation need evaluation in long-term studies.

Overall, continued optimization of ASO design chemistry and safe, effective delivery vehicles hold promise to fully realize the therapeutic potential of this platform for numerous diseases. With over 20 ASO drugs now approved, the future appears bright for nucleic acid medicines.

Get more insights on Antisense Oligonucleotides